Bayer gets FDA fast track status for next-generation blood thinner - Reuters

Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

Register now for FREE unlimited access to Reuters.com

FRANKFURT, Feb 10 (Reuters) - Germany's Bayer (BAYGn.DE) has won fast-track status from U.S. drugs regulators for a new blood thinner designed to prevent certain types of strokes, as it seeks to follow up on the success of its anticoagulant Xarelto.

In a statement on Thursday, Bayer said the Food and Drug Administration granted fast track designation for the review of drug candidate asundexian when tested to prevent a repeat in patients that suffered a non-cardioembolic stroke from clogged vessels.

Bayer's best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson (JNJ.N) holds some rights, will lose patent protection around 2026.

Register now for FREE unlimited access to Reuters.com

Reporting by Ludwig Burger; Editing by Maria Sheahan

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)

Bayer gets FDA fast track status for next-generation blood thinner - Reuters
Read More